HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Revlon investment

This article was originally published in The Rose Sheet

Executive Summary

Board of directors approves $150 mil. cash investment proposed by MacAndrews & Forbes following review by special committee. MacAndrews & Forbes also agrees to continue commitment to provide Revlon with additional cash infusion of up to $40 mil. through December 2003 and up to $65 mil. through December 2004 in the form of a senior unsecured line of credit. Revlon also received necessary amendment to its credit facility to complete the transactions, firm adds. Company has obtained a waiver to its EBITDA and certain other financial covenants for the fourth quarter of 2002, elimination of such covenants for the first three quarters of 2003 and a waiver of the fourth quarter 2003 financial covenants through Jan. 31, 2004. Revlon announced it had been offered the original cash infusion in December (1"The Rose Sheet" Dec. 23, 2002, p. 3)...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010959

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel